Springer Healthcare IME

Master the management of mUC!

How much do you really know?

Metastatic urothelial carcinoma (mUC) is a lethal malignancy with an increasing global incidence. While chemotherapy remains the treatment cornerstone, long-term survival is achieved by only a small group of patients. The evolving landscape has brought forward immunotherapy and targeted agents, reshaping the treatment paradigm, yet the increased variety of options presents a dilemma for clinicians. Selecting the right sequence, appropriately managing adverse events, and establishing effective physician-patient communication can be challenging.

About this program

Led by Program Director Axel Merseburger, together with esteemed field experts we have designed a dynamic learning experience that is both fun, engaging, and clinically relevant.

The Ultimate mUC challenge game and three expert-to-expert interviews will guide you through the intricacies of optimal sequencing, effective management of adverse events, and demonstrate how to better communicate with your patients to improve outcomes.

Be empowered as you dive into an immersive learning environment to unlock invaluable insights and practical knowledge to seamlessly integrate into your clinical practice.

Learning objectives

After participating in this program HCPs will be able to:

Meet the experts

Axel S. Merseburger

Professor of Urology and Chairman of the Department of Urology, 
University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany

Axel Merseburger studied medicine at Hannover Medical School, Hannover, Germany, before completing a residency in surgery and urology at the Eberhard Karls University, Tübingen, Germany, and a research fellowship at the Miller School of Medicine, Miami, FL, USA. Prior to his current role, he was Associate Professor and Professor at Hannover Medical School, and Chairman of the Department of Urology at the University of Lübeck, in Lübeck.

Professor Merseburger is trained in all aspects of open and endoscopic urology and has a specific interest in laparoscopic and robotic-assisted surgery, particularly for the management of prostate, renal and bladder cancer.

Professor Merseburger’s research activity encompasses both molecular and clinical aspects of uro-oncology, focusing on biomarkers and prognostic factors for prostate cancer, renal cell carcinoma, and transitional cell carcinoma. He is Principal Investigator in multiple phase 2 and 3 uro-oncology clinical trials. Professor Merseburger is a member of various uro-oncology organisations, is Chairman of the European Scholarship Programme (ESUP) of the European Association of Urology (EAU), and was the Chairman of the EAU Guideline Group for Lasers and Technologies.

Professor Merseburger is a reviewer and editorial board member for several urology and oncology journals, and serves as Associate Editor of the World Journal of Urology and Editor-in-Chief of the European Journal of Haematology and Oncology and Aktuelle Urologie. He has published widely in the field, having authored or co-authored over 300 peer-reviewed articles.

Disclosures

Professor Merseburger has received honoraria or consultation fees from: AstraZeneca, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EUSAPharma, Ferring Ipsen, MedUpdate, MSD, Merck Serono, Janssen, Pfizer, Takeda, Novartis, Recordati and Roche.

All relevant financial relationships have been mitigated.

Thomas Powles

Professor of Urology Cancer,
University of London, UK

Thomas Powles is a Professor of urology cancer at the University of London and the Director of Barts Cancer Centre, which is one of the UK’s largest Cancer Centres.  He trained as in Oncologist at Imperial College. His MD thesis from the University of London was on mechanisms of resistance to systemic therapy in urology cancer. He has had a major role in the development biomarkers and new drug strategies in urology cancer. This includes multiple EMA and FDA approvals.

Disclosures

Thomas Powles discloses honoraria and/or consultation fees from AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serona, Astellas, Johnson & Johnson, Eisai, Roche, Mashup, and Gilead. He has received grants and/or research support from AstraZeneca, Roche, BMS, Exelixis, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai. He has held a strategic advisory role with AstraZeneca, Roche, BMS, Exelixis, Ipsen, Merck/MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and been a principal investigator for Novartis, Pfizer, AstraZeneca, Roche/Genentech, Eisai. He has also been the recipient of travel and accommodation support from Roche, Pfizer, MSD, AstraZeneca, Ipsen, Gilead, Astellas, and MSD.

All relevant financial relationships of the Faculty have been mitigated.

María José Juan-Fita

Associate Professor of Medical Oncology,
CEU Cardenal Herrera University in Valencia, Spain

María José Juan-Fita has been Associate Professor of Medical Oncology at the CEU Cardenal Herrera University in Valencia, Spain for the past five years, and is a medical oncologist in the Genitourinary Uro-oncology Unit of the Medical Oncology Department at the Hospital Instituto Valenciano de Oncologia in Valencia.

She studied for her medical degree at the Universidad de Valencia in 2005, where she also completed her PhD in 2015 receiving the highest commendation.

In 2009, María José Juan-Fita completed a three-month fellowship in genitourinary tumours at the Memorial Sloan Kettering Cancer Center in New York, USA.

Disclosures

Dr María José Juan–Fita has received honoraria or consultation fees from Janssen, Astellas, BMS, Novartis, Pierre-Fabre, Bayer and MSD.

All relevant financial relationships have been mitigated.

Enrique Grande

Director of the Medical Oncology Program and Clinical Research lead,
MD Anderson Madrid International Cancer Center, Spain

Dr Enrique Grande, MD, PhD, MSc, was recently appointed as Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Madrid International Cancer Center. His research focuses on Genitourinary and Endocrine tumors and he actively collaborates in the development of the Translational Research and Early Drug Development Unit. Dr Grande was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a Master’s degree in the molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO). A published author of more than 150 manuscripts in peer-reviewed journals, Dr Grande is also the founder of the Spanish group for research on orphan and uncommon tumours (GETHI). Dr Grande is Professor at the Francisco de Vitoria University and editor of several international journals. He participated in recent trials in the field of bladder cancer that led to approval of the new drugs we now have available and chairs the steering committee of the IMVIGOR 130 trial.

Disclosures

Dr Enrique Grande has received honoraria or consultation fees from Adacap, AMGEN, Angelini, Astellas, Astra Zeneca, Bayer, Blueprint, Bristol Myers Squibb, Caris Life Sciences, Celgene, Clovis-Oncology, Eisai, Eusa Pharma, Genetracer, Guardant Health, HRA-Pharma, IPSEN, ITM-Radiopharma, Janssen, Lexicon, Lilly, Merck KGaA, MSD, Nanostring Technologies, Natera, Novartis, ONCODNA (Biosequence), Palex, Pharmamar, Pierre Fabre, Pfizer, Roche, Sanofi-Genzyme, Servier, Taiho and Thermo Fisher Scientific.

All relevant financial relationships have been mitigated.

Expert-to-expert interviews

Coming Soon